CliffBio
small molecule

ANGIOVIST 282

DIATRIZOATE MEGLUMINE

Loss of exclusivity—loss of exclusivity
CompanyBayer Healthcare →See this company's full patent-cliff portfolio

Drug detail

Brand nameANGIOVIST 282
Active ingredientDIATRIZOATE MEGLUMINE
Strength60%
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalSeptember 1982
Marketing statusDISCN

More from Bayer Healthcare

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.